Table 8.
Placebo | OnabotA 240 U |
OnabotA 360 U |
|
---|---|---|---|
Number (%) of Patients | |||
Study 1 | |||
Any AEs | 28/36 (77.8%) | 22/36 (61.1%) | 26/36 (72.2%) |
Treatment-related AEs | 5/36 (13.9%) | 6/36 (16.7%) | 5/36 (13.9%) |
Serious AEs | 3/36 (8.3%) | 1/36 (2.8%) | 3/36 (8.3%) |
Study 2 | |||
Any AEs | 25/48 (52.1%) | 30/52 (57.7%) | 28/55 (50.9%) |
Treatment-related AEs | 4/48 (8.3%) | 5/52 (9.6%) | 7/55 (12.7%) |
Serious AEs | 7/48 (14.6%) | 9/52 (17.3%) | 6/55 (10.9%) |
AE = adverse event.